Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Quest Diagnostics To Offer FDA-Cleared Roche PTau217 Blood Test For Alzheimer's Assessment

24 August 2026 · By · Wire by Fusion42

Published

24 August 2026

Topic

opportunities

◆ Sectors

Diagnostics

◆ Geography

United States

◆ Source

Read at rttnews.com →

◆ Verified

Fusion42 · 24 August 2026 · Fusion42 review

Quest Diagnostics will offer the FDA-cleared Roche PTau217 blood test to assess Alzheimer's disease, marking a notable advance in diagnostic testing accessibility in the United States.

This Wire brief sits within Fusion42's coverage of Diagnostics, and 6 sources have reported it between 24 Aug 2026 and 26 Aug 2026.

◆ ◆ The Wire takeaway

You in diagnostics now have a clear FDA pathway for blood-based Alzheimer's tests opening the US clinical market. Leverage this to build earlier disease detection capabilities before others catch up.

◆ Coverage

6 sources · first reported 24 Aug 2026 · latest 26 Aug 2026

◆ Related on Wire

◆ Topics

Diagnosticsalzheimersfda-approvaldiagnosticshealthtechblood-test